Game da-ciwon daji / jiyya / gwaji-na asibiti / cuta / merkel-cell / jiyya
Gwajin Gwani na Gwajin Ciwon Sel na Ciwon Sel
Gwajin gwaji shine karatun bincike wanda ya shafi mutane. Gwajin gwaji a kan wannan jeren don maganin cutar kansar Merkel ne. Duk gwaji akan jerin suna samun tallafi daga NCI.
Babban bayanin NCI game da gwajin asibiti yayi bayanin nau'ikan da matakan gwajin da yadda ake aiwatar dasu. Gwajin gwaji na duba sabbin hanyoyin kariya, ganowa, ko magance cuta. Kuna so kuyi tunani game da shiga cikin gwajin gwaji. Yi magana da likitanka don taimako yayin yanke shawara idan ɗaya ya dace maka.
Gwaji 1-25 na 32 1 2 Na gaba>
Pembrolizumab Idan aka Kwatanta da Tsarin Kulawa da Kulawa da Marasa Lafiya tare da Ciwon Cutar Ciwon Cutar I-III Merkel
Wannan gwajin na lokaci na uku yana nazarin yadda pembrolizumab ke aiki yadda yakamata idan aka kwatanta shi da lura da kulawa wajen kula da marasa lafiya tare da matakin I-III Merkel na ciwon sankara wanda aka cire shi gaba ɗaya ta hanyar tiyata (aka sake shi). Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab, na iya taimaka wa garkuwar jiki ta kai hari ga kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa. Wuri: wurare 286
Pembrolizumab tare da ko ba tare da Tsarin Rashin Tsarin Jiki na Stereotactic ba a Kula da Marasa lafiya tare da Ciwon Cutar Ciwon Cutar Merkel
Wannan gwajin lokaci na bazuwar yayi nazarin yadda kyau pembrolizumab tare da ko ba tare da maganin cututtukan jikin mutum ke aiki ba wajen kula da marasa lafiya da cutar kansa ta kwayar cutar ta Merkel wacce ta bazu zuwa wasu wurare a cikin jiki. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab, na iya taimaka wa garkuwar jiki ta kai hari ga kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa. Magungunan radiation na Stereotactic yana amfani da kayan aiki na musamman don sanya mai haƙuri da isar da radiation ga ciwace-ciwacen daji tare da madaidaicin daidaito. Wannan hanyar na iya kashe ƙwayoyin tumo tare da ƙananan allurai a kan ɗan gajeren lokaci kuma haifar da ƙananan lalacewa ga kayan al'ada. Bayar da pembrolizumab tare da maganin ƙwayar cuta na jikin mutum na iya aiki mafi kyau wajen kula da marasa lafiya da cutar kansa ta ƙwayar ƙwayar ƙwayar cuta ta Merkel.
Wuri: Wurare 246
Nazarin Immuno-far Nazarin don Nazarin Tsaro da Ingancin Nivolumab, da Nivolumab Hadewar Haɗaɗɗen ƙwayoyin cuta masu alaƙa da ƙwayoyin cuta
Dalilin wannan binciken don bincika aminci da tasirin nivolumab, da kuma maganin haɗin nivolumab, don magance marasa lafiya waɗanda ke da ƙwayoyin cuta masu alaƙa da ƙwayoyin cuta. An san wasu ƙwayoyin cuta suna taka rawa wajen samar da ƙari da girma. Wannan binciken zai binciki tasirin magungunan, a cikin marasa lafiyar da ke da nau'ikan ciwace ciwace ci gaba: - Canal na canal na canjin-Ba a sake yin rajista da wannan nau'in ciwon - Ciwon sankarar mahaifa - Epstein Barr Virus (EBV) tabbatacce kansar ciki - Ba a sake yin wannan nau'in ƙari - Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta - Ciwon daji na Penile-Ba a sake yin rajistar irin wannan ciwon ba - Ciwon daji na mata da na mara - Ba a sake yin rajistar wannan nau'in ƙwayar cutar ba - Nasopharyngeal Cancer - Ba a sake yin rajistar wannan nau'in ciwon - Ciwon da Ciwon Cancer - Ba a sake yin rajistar wannan nau'in tumo ba
Wuri: wurare 10
Wannan Nazarin yana kimanta KRT-232, mai ba da labari mai kula da ƙananan ƙwayoyin cuta na MDM2, don Kula da Marasa lafiya Tare da (p53WT) Sel Carcinoma ta Merkel Waɗanda Ba su Yi nasarar Anti-PD-1 / PD-L1 Immunotherapy ba
Wannan binciken yana kimanta KRT-232, wani ɗan ƙaramin maganin ƙwayar ƙwayar ƙwayar ƙwayar cuta ta MDM2, don kula da marasa lafiya tare da Merkel Cell Carcinoma (MCC) waɗanda suka gaza magani tare da aƙalla anti-PD-1 ko anti-PD-L1 immunotherapy. Rashin hana MDM2 wani sabon tsari ne na aiki a cikin MCC. Wannan binciken shine Phase 2, Buɗe-Label, Nazarin Armaya-hannu na KRT-232 a cikin Marasa lafiya tare da p53 Wild-Type (p53WT) Merkel Cell Carcinoma
Wuri: wurare 11
Adjuvant Avelumab a cikin Ciwon Canjin Merkel
Wannan gwajin gwagwarmaya ta zamani yayi nazarin yadda avelumab ke aiki sosai wajan kula da marasa lafiya da kwayar cutar kanjamau ta Merkel wacce ta bazu zuwa sassan kwayar lymph kuma anyi tiyata tare da ko ba tare da maganin radiation ba. Bowayoyin cuta na Monoclonal, kamar avelumab, na iya haɓaka tsarin garkuwar jiki da tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa.
Wuri: wurare 10
QUILT-3.055: Nazarin ALT-803 a cikin Haɗuwa Tare da PD-1 / PD-L1 Mai Kula da Bincike a cikin Marasa lafiya Tare da Ciwon Ciwon Cutar
Wannan shi ne Phase IIb, hannu ɗaya, multicohort, nazarin lakabi mai yawa na ALT-803 a haɗe tare da mai hana duba lafiyar PD-1 / PD-L1 na FDA a cikin marasa lafiya tare da ci gaba da cutar kansa waɗanda suka ci gaba bayan an fara amsawa ta farko jiyya tare da maganin hana shigar PD-1 / PD-L1. Duk marasa lafiya zasu karɓi haɗin haɗin PD-1 / PD-L1 mai hana dubawa tare da ALT-803 har zuwa zagaye 16. Kowane zagaye shine makonni shida a cikin tsawon lokaci. Duk marasa lafiya zasu karɓi ALT-803 sau ɗaya a kowane sati 3. Har ila yau, marasa lafiya za su karɓi wannan mai hana shingen binciken da suka karɓa yayin maganin da suka gabata. Binciken rediyo zai faru a ƙarshen kowane zagaye na jiyya. Jiyya zai ci gaba har zuwa shekaru 2, ko kuma har sai masu haƙuri sun tabbatar da ci gaba da cutar ko cutar da ba za a yarda da ita ba, ta janye izinin, ko kuma idan Mai Binciken ya ji cewa ba shi da mahimmancin haƙuri ga ci gaba da jinya. Za a bi marasa lafiya don ci gaba da cutar, hanyoyin kwantar da hankali, da rayuwa ta hanyar watanni 24 da suka gabata na gwamnatin farko da maganin farko na maganin.
Wuri: Wurare 9
Nazarin NKTR-262 a cikin Haɗuwa Tare da NKTR-214 da Tare da NKTR-214 Nari Nivolumab a cikin Marasa lafiya Tare da Ci Gaban Ci Gaban orabi'a ko astarancin Tumor na Tattalin Arziki
Marasa lafiya za su sami intra-tumoral (IT) NKTR-262 a cikin maganin hawan sati 3. Yayin ƙaddamar kashi na kashi na 1 na gwajin, NKTR-262 za a haɗe shi tare da tsarin sarrafa bempegaldesleukin. Bayan ƙaddamar da shawarar kashi na 2 na zamani (RP2D) na NKTR-262, tsakanin marasa lafiya 6 da 12 na iya shiga cikin RP2D don ƙarin bayanin yanayin aminci da haƙuri game da haɗin NKTR 262 da bempegaldesleukin (doublet) ko NKTR 262 da bempegaldesleukin a hade tare da nivolumab (triplet) a cikin Cohorts A da B, bi da bi. A cikin ɓangaren fadada kashi na 2 na zamani, za a kula da marasa lafiya da ninki biyu ko sau uku a cikin yanayin sake dawowa / ƙin yarda da layin farko na farfadowa.
Wuri: wurare 14
Nazarin INCMGA00012 a cikin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (POD1UM-201)
Dalilin wannan binciken shine don tantance aikin asibiti da amincin INCMGA00012 a cikin mahalarta tare da ci gaba / metastatic Merkel cell carcinoma (MCC).
Wuri: Wurare 8
PEN-221 a cikin Somatostatin Receptor 2 Bayyana Ciwon Ciwon Ciki Ciki har da Neuroendocrine da Cellananan Lanƙarar Huhu
Yarjejeniyar PEN-221-001 lakabi ce mai budewa, bincike mai yawa na 1 / 2a na nazarin PEN-221 a cikin marasa lafiya tare da SSTR2 wanda ke bayyana ci gaban gastroenteropancreatic (GEP) ko huhu ko thymus ko wasu cututtukan daji na ƙananan neuroendocrine ko ƙananan ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayarfancincin ɗan adam a cikin layi tare da lakabi na bude-lakabi, mai yawan bincike na 1 / 2a wanda ke nazarin PEN-221 a cikin marasa lafiya tare da SSTR2 wanda ke bayyana ci gaba na gastroenteropancreatic (GEP) ko huhu ko thymus ko wasu cututtukan ƙwayoyin cuta ko ƙananan ƙwayoyin cuta na huhu.
Wuri: Wurare 7
Nazarin Lokaci na 1/2 na Cikin Alurar riga kafi Tare da Tremelimumab da IV Durvalumab Polyarin PolyICLC a cikin Batutuwa Tare da Ci gaba, Mai aunawa, Ciwon Cutar Cancer
Wannan sigar buɗe-lakabi ce, bincike mai yawa na 1/2 na CTLA-4 antibody, tremelimumab, da PD-L1 antibody, durvalumab (MEDI4736), a haɗe tare da ƙari microenvironment (TME) modulator polyICLC, a TLR3 agonist, a cikin batutuwan da ke fama da ciwan kansa, wanda za'a iya auna shi, wanda yake da sauƙin rayuwa.
Wuri: Wurare 6
Intratumoral AST-008 Haɗe tare da Pembrolizumab a cikin Marasa lafiya Tare da Ciwon Tumurai Masu Inganci
Wannan shi ne lokaci na 1b / 2, lakabin bude, fitina mai yawan gaske wanda aka tsara don kimanta aminci, jurewa, magungunan magani, magani da inganci na farko na allurar allurar cikin jiki ta AST-008 ita kaɗai kuma a haɗe tare da intravenous pembrolizumab a cikin marasa lafiya tare da ci gaba da ciwan ciwuka. Lokaci na 1b na wannan gwajin shine nazarin haɓaka 3 + 3 na haɓaka haɓakawa ko kimantawa na matakin AST-008 wanda aka bayar tare da tsayayyen kashi na pembrolizumab. Lokaci na 2 ƙungiya ce ta faɗaɗa don ƙara kimanta AST-008 da aka bayar a haɗe tare da pembrolizumab a cikin wani keɓaɓɓen yawan jama'a don bayar da ƙididdigar farko na inganci ga marasa lafiya waɗanda suka karɓa a baya kuma ba su amsa anti-PD-1 ko anti-PD-L1 antibody far.
Wuri: Wurare 7
Gwajin Injections na Intratumoral na TTI-621 a cikin Batutuwa Tare da orsarfin Twayar Tumbi da ractarfafawa da Mycosis Fungoides
Wannan babban shafi ne, lakabi ne na budewa, binciken lokaci na 1 wanda aka gudanar don gwada allurar intratumoral na TTI-621 a cikin batutuwan da suka sake dawowa da kuma tsayayyar hanya mai yuwuwar samun ciwace-ciwacen ƙwayoyi ko mycosis fungoides. Za a gudanar da binciken a sassa biyu daban-daban. Sashe na 1 shine Tsarin Haɓaka Dose kuma Sashe na 2 shine Expaddamar Fadakarwa. Dalilin wannan binciken shine a siffanta martabar lafiyar TTI-621 da kuma ƙayyade ƙimar mafi kyau da kuma jadawalin isarwar TTI-621. Bugu da ƙari, za a kimanta amincin da antitumor na TTI-621 a haɗe tare da wasu wakilan anti-cancer ko radiation.
Wuri: Wurare 5
Nazarin RP1 Monotherapy da RP1 a cikin Haɗuwa Tare da Nivolumab
RPL-001-16 shine 1/2 na Phase, lakabin buɗewa, haɓaka kashi da faɗaɗa nazarin asibiti na RP1 shi kaɗai kuma a haɗe tare da nivolumab a cikin batutuwan manya tare da ci gaba da / ko ciwan ƙura mai ƙyama, don ƙayyade matsakaicin haƙuri mai ƙarfi (MTD) da kuma shawarar kashi na 2 na zamani (RP2D), da kuma kimanta ingancin farko.
Wuri: Wurare 6
Talimogene Laherparepvec tare da ko ba tare da Hypofractionated Radiation Far a Kula da Marasa lafiya tare da Melanoma Metastatic, Merkel Cell Carcinoma, ko Sauran Tananan Tumor
Wannan gwajin lokaci na bazuwar na nazarin illolin talimogene laherparepvec da kuma ganin yadda yake aiki tare ko ba tare da maganin raunin raunin hypofraction ba a kula da marasa lafiya da melanoma na fata, carcinoma cell na Merkel, ko wasu ƙwayoyin cuta masu ƙarfi waɗanda suka bazu zuwa wuraren da basu dace da cirewar ba . Magungunan da aka yi amfani da su a cikin rigakafin rigakafi, kamar talimogene laherparepvec, na iya ƙarfafa garkuwar jiki don yaƙar ƙwayoyin cuta. Magungunan radiation mai rarrabuwa yana samar da mafi girman maganin radiation a cikin ɗan gajeren lokaci kuma yana iya kashe ƙarin ƙwayoyin ƙari kuma suna da ƙananan sakamako masu illa. Ba a san shi ba har yanzu idan ba talimogene laherparepvec tare da ko ba tare da hypofractionated radiation zai yi aiki mafi kyau wajen kula da marasa lafiya tare da cututtukan ƙwayoyin cuta, ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayarfancin ƙwayar ƙwayoyin cuta, ko kuma ba tare da ba da magani ba zai iya aiki mafi kyau a cikin kula da marasa lafiya tare da cututtukan ƙwayoyin cuta, ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayarfancin edozi, ko kuma ba tare da ba da magani ba, zai iya aiki mafi kyau a cikin kula da marasa lafiya tare da cututtukan ƙwayoyin cuta, ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayarfancincin da aka yi amfani da ita da ƙwayoyin cuta, ko kuma ba tare da maganin ba.
Wuri: Wurare 3
FT500 a matsayin Monotherapy kuma a cikin Haɗuwa Tare da Masu hana Ilimin Dubawa a cikin Batutuwa Tare da Ciwon Tumurai Masu Inganci
FT500 abu ne da ba-shiryayye ba, samfurin NK wanda aka samu daga iPSC wanda zai iya hade rigakafin da zai dace da shi, kuma yana da damar shawo kan hanyoyin da yawa na masu hana masu kariya (ICI). Bayanai na yau da kullun suna ba da hujjoji masu gamsarwa waɗanda ke goyan bayan binciken asibiti na FT500 a matsayin monotherapy kuma a haɗe tare da ICI a cikin batutuwa masu ciwace-ciwacen ci gaba.
Wuri: Wurare 3
Tacrolimus, Nivolumab, da Ipilimumab a cikin Kula da Masu karɓar koda tare da Zaɓaɓɓun Marassa Lafiya ko Ciwon Cutar Canza
Wannan gwajin na lokaci na nazarin yadda tacrolimus, nivolumab, da ipilimumab ke aiki yadda yakamata wajen magance masu karɓar dashen koda tare da cutar kansa wanda ba za a iya cire shi ta hanyar tiyata ba (ba za a iya tantance shi ba) ko kuma ya bazu zuwa wasu wurare a cikin jiki (metastatic). Tacrolimus na iya dakatar da ci gaban ƙwayoyin cuta ta hanyar toshe wasu ƙwayoyin enzymes da ake buƙata don ci gaban kwayar halitta. Immunotherapy tare da kwayoyin cuta na monoclonal, irin su nivolumab da ipilimumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin tumo don girma da yaɗuwa. Ba da tacrolimus, nivolumab, da ipilimumab na iya yin aiki mafi kyau wajen kula da masu karɓar dashen koda tare da cutar kansa idan aka kwatanta da cutar sankara, tiyata, aikin fida, ko kuma hanyoyin kwantar da hankali.
Wuri: Wurare 2
Nivolumab da Ipilimumab tare da ko ba tare da Tsarin Radiation na Jikin Stereotactic ba a Kula da Marasa lafiya tare da Maimaita Ciwon Cutar Ciwon Sikila ko Mataki na IV
Wannan gwajin lokaci na bazuwar yayi nazarin yadda kyau nivolumab da ipilimumab tare da ko ba tare da maganin cututtukan fitilar jikin mutum ba wajen kula da marasa lafiya da cutar kansa ta kwayar halitta ta Merkel wacce ta dawo ko kuma mataki na IV. Immunotherapy tare da kwayoyin cuta na monoclonal, irin su nivolumab da ipilimumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin tumo don girma da yaɗuwa. Magungunan radiation na Stereotactic yana amfani da kayan aiki na musamman don sanya mai haƙuri da isar da radiation ga ciwace-ciwacen daji tare da madaidaicin daidaito. Wannan hanyar na iya kashe ƙwayoyin tumo tare da ƙananan allurai a kan ɗan gajeren lokaci kuma haifar da ƙananan lalacewa ga kayan al'ada. Ba da nivolumab da ipilimumab tare da ko ba tare da maganin ƙwayar cuta na jikin mutum ba na iya aiki mafi kyau wajen kula da marasa lafiya da cutar kansa ta ƙwayar salula.
Wuri: Wurare 2
Pembrolizumab da Radiation Far don Kula da ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta
Wannan gwaji na lokaci na II yana nazarin illolin illa da yadda pembrolizumab da maganin raɗaɗɗa ke aiki wajen kula da marasa lafiya da ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ta Merkel wacce ta bazu zuwa wasu wurare a cikin jiki (metastatic). Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab, na iya taimaka wa garkuwar jiki ta kai hari ga kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa. Radiation far yana amfani da hasken rana mai ƙarfi don kashe ƙwayoyin tumo da ƙyamar ciwace-ciwacen. Bada pembrolizumab da maganin raɗaɗɗiya na iya ƙara fa'idar pembrolizumab.
Wuri: Cibiyar Cancer ta Stanford Palo Alto, Palo Alto, California
Nazarin LY3434172, PD-1 da PD-L1 Bishop na Musamman, a Ciwon Ciwon Cutar
Babban manufar wannan binciken shine a kimanta aminci da jure maganin binciken LY3434172, PD-1 / PD-L1 bispecific antibody, a cikin mahalarta tare da ciwace ciwace mai ƙarfi.
Wuri: Cibiyar Cancer ta MD Anderson, Houston, Texas
Sashin Kwayar Kwayar Kwayar Kwayoyin cuta (Tumbor Infiltrating Lymphocytes) don Kula da Ci Gaban Ci Gaban Gida, Ciwon Metastatic, ko Raunin Marar Cutar Ciki
Wannan gwajin na lokaci na II yana nazarin yadda ingantaccen kwayar halitta (tare da ƙwayar lymphocytes da ke kutsawa) ke aiki don maganin kansar da ta bazu zuwa kusa da nama ko ƙwayoyin lymph (masu ci gaba na cikin gida), sun bazu zuwa wasu sassan jiki (metastatic), ko dawo (maimaitawa) Wannan gwajin ya shafi shan kwayoyin halitta da ake kira lymphocytes (wani nau'in farin jini) daga ciwace-ciwacen marasa lafiya, a bunkasa su a dakin gwaje-gwaje da adadi mai yawa, sannan a mayar da kwayoyin ga mai haƙuri. Ana kiran waɗannan ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyin ƙwayoyinku. Ba da magungunan ƙwayoyin cuta kafin ƙwayoyin cuta na ɗan lokaci na danƙare tsarin garkuwar jiki don haɓaka damar da ƙwayoyin gwagwarmaya na ƙari za su iya rayuwa cikin jiki. Bayar da aldesleukin bayan gudanarwar kwayar halitta na iya taimaka wa ƙwayoyin cuta masu yaƙar ƙari su rayu tsawon rai.
Wuri: Jami'ar Pittsburgh Cibiyar Cancer (UPCI), Pittsburgh, Pennsylvania
Nivolumab da Radiation Far ko Ipilimumab azaman Adjuvant Far a Kula da Marasa lafiya tare da Merkel Cell Cancer
Wannan gwajin na lokaci yana nazarin illolin da kuma yadda nivolumab ke aiki yayin da aka ba su tare da maganin fuka-fuka ko ipilimumab azaman magani na adjuvant wajen kula da marasa lafiya da cutar kansa ta sel. Immunotherapy tare da kwayoyin cuta na monoclonal, irin su nivolumab da ipilimumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin tumo don girma da yaɗuwa. Radiation radiation yana amfani da hasken rana mai ƙarfi mai ƙarfi, hasken gamma, neutron, protoni ko wasu hanyoyin don kashe ƙwayoyin tumo da rage jijiyoyin. Ba da nivolumab tare da maganin fuka-fuka ko ipilimumab bayan tiyata na iya kashe duk sauran ƙwayoyin tumo.
Wuri: Cibiyar Kula da Ciwon Kwaleji ta Jami'ar Jihar Ohio, Columbus, Ohio
Pembrolizumab (MK-3475) azaman Far-line na farko don Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta Merkel (MK-3475-913)
Wannan sigar hannu guda ce, mai lakabin buɗaɗɗu, mai yawan fili, inganci, da kuma nazarin lafiyar pembrolizumab a cikin manya da kuma mahalarta yara tare da tsohuwar ƙwayar cutar Merkel Cell Carcinoma (MCC). Babban makasudin gwajin shine a tantance kimar mayar da martani, kamar yadda aka tantance ta hanyar bita ta tsakiya mai zaman kanta ta hanyar Respididdigar onseididdigar Amincewa a cikin Sigar umananan Tumors na 1.1 (RECIST 1.1) da aka gyara don bin mafi ƙarancin raunuka 10 da kuma iyakar 5 rauni kowane sashin jiki, bin gudanarwar pembrolizumab.
Wuri: Laura da Ishaƙu Perlmutter Cancer Center a NYU Langone, New York, New York
Kwayoyin Tsarin Tsarin Tsarin Tsarin Tsarin Tsarin Kwayoyin Halitta (FH-MCVA2TCR) a cikin Kula da Marasa lafiya tare da Ciwon Cutar Sel na Merkel
Wannan gwajin I / II na zamani yana nazarin illolin ƙwayoyin halittar da aka canza (FH-MCVA2TCR) da kuma ganin yadda suke aiki da kyau wajen kula da marasa lafiya da cutar kansa ta Merkel wacce ta bazu zuwa wasu sassan jiki (metastatic) ko kuma wanda ba zai iya ba cire shi ta hanyar tiyata (wanda ba za'a iya tantancewa ba). Sanya kwayar halitta wacce aka kirkira a dakin gwaje-gwaje a cikin kwayoyin kariya na iya inganta karfin jiki don yakar cutar kansar Merkel.
Wuri: Fred Hutch / Jami'ar Washington Cancer Consortium, Seattle, Washington
Nazarin Tsaro da Haƙuri na INCAGN02390 a cikin Zaɓi Cutar Gaggawa
Dalilin wannan binciken shine don ƙayyade aminci, juriya, da ingancin farko na INCAGN02390 a cikin mahalarta tare da zaɓaɓɓen cututtukan ci gaba.
Wuri: Cibiyar Kiwon Lafiya ta Jami'ar Hackensack, Hackensack, New Jersey
Abexinostat da Pembrolizumab a Kula da Marasa lafiya tare da MSI-High Local Advanced ko Ciwon umananan Tumor
Wannan gwajin na lokaci yana nazarin mafi kyawun magani da sakamako masu illa na abexinostat da yadda yake aiki tare da bayarwa tare da pembrolizumab wajen kula da marasa lafiya tare da rashin ƙarfin microsatellite rashin ƙarfi (MSI) ƙaƙƙarfan ƙwayoyin cuta waɗanda suka bazu zuwa nama kusa ko ƙwayoyin lymph (na cikin gida gaba) ko wasu wurare a cikin jiki (metastatic). Abexinostat na iya dakatar da ci gaban ƙwayoyin tumo ta hanyar toshe wasu ƙwayoyin enzymes da ake buƙata don ci gaban kwayar halitta. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab, na iya taimaka wa garkuwar jiki ta kai hari ga kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa. Bada abexinostat da pembrolizumab na iya aiki mafi kyau wajen kula da marasa lafiya da ciwan ciwuka.
Wuri: Cibiyar Kula da Lafiya ta UCSF-Mount Zion, San Francisco, California
1 2 Gaba>
